People: Aegerion Pharmaceuticals Inc (AEGR.O)

AEGR.O on Nasdaq

30.00USD
25 Jul 2014
Price Change (% chg)

$0.91 (+3.13%)
Prev Close
$29.09
Open
$28.97
Day's High
$30.12
Day's Low
$28.75
Volume
827,192
Avg. Vol
1,064,739
52-wk High
$101.00
52-wk Low
$26.25

Search Stocks

Sumeray, Mark 

Brief Biography

Dr. Mark Sumeray, MD, serves as Chief Medical Officer of Aegerion Pharmaceuticals, Inc., since August 2011. From November 2009 to July 2011, Dr. Sumeray served as Vice President, Cardiovascular/Metabolics U.S. Medical at Bristol-Myers Squibb (a pharmaceutical company). From December 2004 to November 2009, Dr. Sumeray held various positions at The Medicines Company, including Vice President and Business Unit Co-Leader, Vice President, Medical Business Development, and Vice President Clinical Development and Head of Medical Science. From September 2000 to October 2004, Dr. Sumeray served as worldwide Vice President of Clinical Development for the Ethicon Franchise of Johnson & Johnson. Dr. Sumeray holds a B.S. degree, an M.S. degree in surgery and an M.D. degree from the University College London. Dr. Sumeray is a Fellow of the Royal College of Surgeons, or FRCS, in the United Kingdom.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
600,400 -- 2,472,610 3,073,010

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 40,000 2,188,470.00
Name Fiscal Year Total

David Scheer

--

Marc Beer

7,036,540

Mark Fitzpatrick

1,888,490

Craig Fraser

1,979,770

Anne Cook

2,258,030

Martha Carter

1,520,990
As Of 30 Dec 2013
Search Stocks